1481642-14-1

Basic information

• Product Name: (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid
• Synonyms: (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid;(9H-Fluoren-9-yl)MethOxy]Carbonyl D-Glu(OMe)-OH
• CAS NO: 1481642-14-1
• Molecular Formula: C21H21NO6
• Molecular Weight: 383.39454
• Mol File: 1481642-14-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid(1481642-14-1)
• EPA Substance Registry System: (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid(1481642-14-1)

Safety Data

• Hazardous Substances Data: 1481642-14-1(Hazardous Substances Data)

Usage

General Description

The chemical compound (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid is a complex organic molecule with a long and detailed name. It is a derivative of the amino acid alanine, with additional groups attached to its structure including a fluorenylmethoxy carbonyl group and a methoxy group. (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid has potential applications in the field of pharmaceuticals and drug development, as it may have biological activity or be used in the synthesis of other compounds. The specific properties and uses of this compound would depend on further research and testing.

Upstream product

• 1499-55-4 L-glutamic acid 5-methyl ester 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 

Downstream Products

• 4425-82-5 9-methylene-fluorene 
• 104091-09-0 (S)-2-[{({9H-fluoren-9-yl}methoxy)carbonyl}amino]pentanedioic acid 

Relevant articles and documents

Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin

Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy. It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans. Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies. The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain. The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac. In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation. Moreover, compound 45 rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease. This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.

METHOD FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(PYRIDIN-2-YL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPIN-4-YL]-PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN SAID METHOD

The present invention relates to a method for preparing 3- [ ( 4S ) -8-bromo-l-methyl-6- (pyridin-2-yl ) -4H-imidazo [1,2- a] [ 1, 4 ] benzodiazepin-4-yl ] -propionic acid methyl ester starting from 3- [ (3S) -7-bromo-2-oxo-5- (pyridin-2-yl ) -2, 3-dihydr